JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals

Vandana Singh
1 min read
0
In this article:

  • Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) received written notice from Janssen, a unit of Johnson & Johnson (NYSE: JNJ), to terminate their rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement.

  • The companies are working to transition the program and associated data to Arrowhead.

  • ARO-PNPLA3 is an investigational RNA interference (RNAi) therapeutic developed using Arrowhead's proprietary TRiM platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) for non-alcoholic steatohepatitis (NASH).

  • ARO-PNPLA3 is currently in Phase 1 clinical study.

  • After a single dose in Phase 1 clinical study, ARO-PNPLA3 showed a dose-dependent mean reduction in liver fat of up to 40% in patients homozygous for the I148M mutation.

  • No apparent treatment-emergent increases in triglycerides or LDL cholesterol.

  • In 2021, Arrowhead announced a deal with GSK plc (NYSE: GSK), under which GSK will develop and market Arrowhead's potential treatment for patients with fatty liver disease NASH.

  • At that time, the drug candidate ARO-HSD is currently in an early-to-mid stage trial for NASH.

  • Price Action: ARWR shares are down 0.83% at $33.39 on the last check Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories